bioRxiv · 10.1101/2020.06.02.130161
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
Abstract
SARS-CoV-2 is the etiologic agent of COVID-19, currently causing a devastating pandemic for which pharmacological interventions are urgently needed. The virus enters host cells through an interaction between the spike glycoprotein and the angiotensin converting enzyme 2 (ACE2) receptor. Directly preventing this interaction presents an attractive possibility for suppressing SARS-CoV-2 replication. Here we report the isolation and characterization of an alpaca-derived single domain antibody fragment, Ty1, that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike, directly preventing ACE2 engagement. The nanobody binds with high affinity in the low nM range to the RBD, occluding ACE2. A cryo-electron microscopy structure of the bound complex at 2.9 Å resolution reveals that Ty1 binds to an epitope on the RBD accessible in both the ‘up’ and ‘down’ conformations and that Ty1 sterically hinders RBD-ACE2 binding. This 12.8 kDa nanobody does not need an Fc domain to neutralize SARS-CoV-2, and can be expressed in high quantities in bacteria, presenting opportunities for manufacturing at scale. Ty1 is therefore an excellent candidate as an intervention against COVID-19.Competing Interest StatementThe authors have declared no competing interest.View Full Text
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Hanke, L., Perez Vidakovics, M. L., Sheward, D., Das, H., Schulte, T., Moliner Morro, A., Corcoran, M., Achour, A., Karlsson Hedestam, G., Hällberg, B. M., Murrell, B., McInerney, G. M.. 2020-06-02. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. https://doi.org/10.1101/2020.06.02.130161
Cite the original work for its findings. Save a collection to share your selection of sources.